Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

Beijing SL Pharmaceutical Revenue

Beijing SL Pharmaceutical had revenue of 139.27M CNY in the quarter ending September 30, 2026, a decrease of -9.50%. This brings the company's total for the last twelve months to 555.64M, down -3.97% year-over-year. In the year 2025, Beijing SL Pharmaceutical had annual revenue of 623.64M, down -5.57%. That makes Beijing SL Pharmaceutical the 24,107th largest company in the world by revenue and 4,336th in China.

• Revenue (ttm): 555.64M
• Revenue Growth: -3.97%
• P/S Ratio: 9.30
• Revenue / Employee: 616.69K
• Employees: 901
• Market Cap: 5.17B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Industry 612.49M 98.2%
• Unallocated Others 11.15M 1.8%

By Geography

Chart

• East China 185.03M 29.7%
• Central South China 167.20M 26.8%
• North China 113.35M 18.2%
• North East China 62.29M 10.0%
• South West China 59.40M 9.5%
• North West China 32.20M 5.2%
• Regional and Export Business 4.17M 0.7%

Fiscal year ended Dec 31, 2025 See the full Beijing SL Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	623.64M	-36.78M	-5.57%
Dec 31, 2024	660.42M	-357.94M	-35.15%
Dec 31, 2023	1.02B	-31.81M	-3.03%
Jan 1, 2023	1.05B	-164.65M	-13.55%
Jan 1, 2022	1.21B	102.08M	9.17%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error